mk-1

MK-1-907 is a potential bioactive agent. No further details yet.

MK-1064 (Urokinase inhibitor 1) is a selective orexin 2 receptor antagonist (2-SORA).

MK-1468, a highly selective and brain-penetrant LRRK2 inhibitor, exhibits an IC50 of 0.8 nM and is utilized in the study of Parkinson's disease [1].

MK-142 dimethyl sulfonate is a biologic active agent with antiarrhythmic properties, and the content of MK-142 is relatively high in cardiac muscle compared to that in skeletal muscle, indicating that the substance tested has a high affinity with cardiac

MK-1220 is a novel Macrocyclic Inhibitor of Hepatitis C Virus NS3/4A Protease with Improved Preclinical Plasma Exposure.

MK-1775 hemihydrate is a WEE1 inhibitor with potential antineoplastic sensitizing activity.

MK-1421 is a potent and selective sstr3 antagonist.

MK1496 is a n orally bioavailable Polo-like kinase 1 (Plk1) inhibitor with potential antineoplastic activity. Polo-like kinase 1 inhibitor MK1496 selectively inhibits Plk1, inducing selective G2/M arrest followed by apoptosis in a variety of tumor cells while causing reversible cell arrest at the G1 and G2 stage without apoptosis in normal cells. Plk1, named after the polo gene of Drosophila melanogaster, is a serine/threonine protein kinase involved in regulating mitotic spindle function in a non-ATP competitive manner. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus).

Dexamethasone is a glucocorticoid receptor agonist and IL receptor modulator with anti-inflammatory, immunosuppressive, and apoptosis-inducing activities. It inhibits the production of inflammatory miRNA-155 exosomes in macrophages, significantly reduces inflammatory cytokine expression in neutrophils and monocytes, suppresses LPS-induced macrophage inflammation, and induces autophagy. It is commonly used to induce animal models of depression, muscle atrophy, and hypertension, and holds potential in COVID-19 research.

LX7101 is an effective inhibitor of LIMK and ROCK2 (IC50: 24, 1.6, and 10 nM for LIMK1, LIMK2, and ROCK2, respectively). It also inhibits PKA (IC50 <1 nM).

LX-7101 hydrochloride is a potent LIMK and ROCK2 inhibitor with antihypertensive activity, inhibits LIMK1/2, ROCK, PKA, and can be used to study glaucoma.

Adavosertib (MK-1775) is a small molecule inhibitor of the checkpoint kinase WEE1 (IC50: 5.2 nM). It hinders the G2 DNA damage checkpoint.

R-10015 is a highly potent and selective LIMK inhibitor that blocks LIMK by binding to the ATP-binding pocket. It inhibits human LIMK1 with an IC50 value of 38 nM. It also exerts broad-spectrum antiviral effects and may be used in HIV infection research.

TH-263 is inactive toward both LIMK1 and LIMK2 and thus can be used as negative control for TH-257, and is a diaryl sulfonamide derivative.

VUT-MK142 is a new cardiomyogenic small molecule promoting the differentiation of pre-cardiac mesoderm into cardiomyocytes,which may be useful to differentiate stem cells into cardiomyocytes for cardiac repair.

Doravirine (MK-1439) is a non-nucleoside reverse transcriptase inhibitor used for the treatment of HIV/AIDS.

Calderasib (MK-1084) is a selective KRAS G12C inhibitor with an IC50 value of 1.2 nM . Calderasib (MK-1084) exhibits significant anticancer activity, and it can be employed either as a monotherapy or in combination with the PD-1 inhibitor Pembrolizumab, providing a versatile approach for the investigation of KRAS-mutant driven cancers.

ARQ-531 is a potent and orally active BTK inhibitor with potential antineoplastic activity, with IC50s of 0.85 nM and 0.39 nM for WT-BTK and C481S-BTK, respectively.

Ubrogepant (MK-1602) is a calcitonin gene-related peptide receptor antagonist used in acute migraine treatment studies.

XMD8-92 is an effective and specific BMK1/ERK5 inhibitor (Kd: 80 nM).

Indacrinone is an investigational diuretic.

LIMK1 inhibitor 2 (compound 41) is a LIMK1 inhibitor with an IC50 value of 9 μM.

LIMK1 inhibitor1 (compound 24) is a LIMK1 inhibitor, potentially useful for cancer research.

MK16 is a lipid material designed for constructing lipid nanoparticles capable of penetrating the blood-brain barrier for mRNA delivery.